Tilithia serves as the Vice President, Quality for the Federation. In this role, she supports FAH’s regulatory and legislative efforts related to the development, implementation, and evaluation of quality measures and value-based programs across public and private initiatives.  Tilithia also staffs the Federation’s Quality Committee, Covid-19 Vaccines & Therapeutics Task Force, Health Equity Task Force, and Health Information Technology Committee.

Prior to joining the Federation, Tilithia was the Director, Quality Payment & Delivery Reform at GlaxoSmithKline (GSK), where she led an integrated quality strategy enterprise-wide for the vaccines, HIV, Consumer Health and US pharmaceutical businesses. She also played an instrumental role in prioritizing health equity, professional development, and diverse representation as the co-chair of GSK’s Managed Markets & Governments Affairs Inclusion & Diversity Board. Additionally, Tilithia has held quality leadership roles in the Evidence-based Medicine Practice at Avalere Health, the American Academy of Dermatology, and the American College of Cardiology. She began her pursuit of quality health care and quality improvement at the National Committee for Quality Assurance.

She has a Bachelor of Science degree in political science from Lincoln University in Pennsylvania.